This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response.
There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer. In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
We can conclude that it isn’t necessary for all men taking Zytiga plus prednisone to continue ADT, but some men will see an increase in their testosterone levels, warranting close monitoring and adding back ADT to their treatment.
After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment.
Findings confirm the better strategy for salvage therapy after failed surgery for prostate cancer is ADT along with radiotherapy,
The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.
The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.
Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).
Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.
The use of apalutamide (Erleada) improved radiographic progression-free survival with a 52% reduction in risk of death or radiographic progression; that benefit was observed across all subgroups analyzed in the TITAN TRIAL for men with progressing prostate cancer that is still hormone sensitive. The median radiographic progression-free survival was not reached in the apalutamide group and was 22.1 months in the placebo group.
The Man Cave is a unique patient care model that combines educational resources, emotional support, and the latest medical technology. They are creating sports-themed facilities where men can feel at ease, complete with a team of friends, medical professionals, educators, and advocates ready to help them take control of their healthcare journey.
The practice of “surprising” patients with unexpected, exorbitant bills needs to stop and insurance companies need to become responsible for reasonable out of network medical expenses
As early as 2013, we have known that a lower baseline prostate-specific antigen (PSA) is associated with a higher overall survival benefit from Provenge (sipuleucel-T)
Prostate cancer treatments have been targeting the androgen receptor for over 80 years, and the vast majority of our new treatments also continue to target the androgen receptor. Prostate cancer treatments have failed to include new classes of treatments when compared to other cancers.
There was a small clinical trial, by Mark Ratain, M.D., of the University of Chicago, that suggests that it is possible to take a lower dose of Zytiga (abiraterone) along with a low-fat breakfast and achieve a response similar to the one we would expect to see with a full dose on an empty stomach.
How best to treat oligometastatic prostate cancer is still not clear, but there are several on-going studies designed to determine what should be best practices. Although not yet completed, these studies do indicate that metastasis-directed therapy (MDT) and local therapy targeted to the primary tumor (in the prostate gland) may be of benefit in the setting of oligometastatic disease.
Dr. Howard Soule of the Prostate Cancer Foundation has long discussed the Three Ds of successful cancer treatment. Using Dr. Soule’s paradigm really allows us to understand the cancer treatment process and more importantly where we are failing in treating patients.
Debulking, or lowering the tumor load, might provide over all survival benefits for men diagnosed with prostate cancer.
African American men face many different health disparities with most of the disparities being weighed against them. There is one notable exception, African American (AA) men have a huge, significant overall survival benefit when given Sipuleucel-T (Provenge) equal to 9.5 months over their Caucasian counterparts!
The National Comprehensive Cancer Network (NCCN) serves as a generally accepted cookbook or road map for doctors as they put together treatment plans for their patients. The NCCN relies on evidence-based findings as well as FDA approvals. Their guidelines create the standard of care for the treatment of serious disease, including cancer.
As it just did, the NCCN periodically releases updates to their guidelines for prostate cancer treatment.